Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis
Abstract Background Data on the treatment of patients with hepatitis C virus (HCV)/human immunodeficiency virus (HIV) coinfection remains limited. A comprehensive analysis was performed to evaluate the efficacy and safety of ombitasvir (OBV)/paritaprevir (PTV)/ritonavir(r) ± dasabuvir (DSV) ± ribavi...
Main Authors: | Jingjing Wu, Peng Huang, Haozhi Fan, Ting Tian, Xueshan Xia, Zuqiang Fu, Yan Wang, Xiangyu Ye, Ming Yue, Yun Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-01-01
|
Series: | Virology Journal |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12985-018-1114-4 |
Similar Items
-
Efficacy of treatment with Ombitasvir, Paritaprevir / r + Dasabuvir over 8 versus 12 weeks in chronic HCV hepatitis genotype 1b
by: Mircea Manuc, et al.
Published: (2021-03-01) -
Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4
by: Daniel H. Leung, et al.
Published: (2018-11-01) -
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis
by: Mario G. Pessoa, et al.
Published: (2018-11-01) -
Sustained virological response 12 versus sustained virological response 24 as evaluation endpoints in chronic hepatitis C virus Egyptian patients treated with sofosbuvir-based regimens
by: Maha M Elsabaawy, et al.
Published: (2019-01-01) -
Factors and HCV treatment outcomes associated with smoking among people who inject drugs on opioid agonist treatment: secondary analysis of the PREVAIL randomized clinical trial
by: Irene Pericot-Valverde, et al.
Published: (2020-12-01)